106 related articles for article (PubMed ID: 34026426)
21. Calcium Carbonate Core-Shell Particles for Incorporation of
Muslimov AR; Antuganov DO; Tarakanchikova YV; Zhukov MV; Nadporojskii MA; Zyuzin MV; Timin AS
ACS Appl Mater Interfaces; 2021 Jun; 13(22):25599-25610. PubMed ID: 34028266
[TBL] [Abstract][Full Text] [Related]
22. A Review of Theranostics: Perspectives on Emerging Approaches and Clinical Advancements.
Burkett BJ; Bartlett DJ; McGarrah PW; Lewis AR; Johnson DR; Berberoğlu K; Pandey MK; Packard AT; Halfdanarson TR; Hruska CB; Johnson GB; Kendi AT
Radiol Imaging Cancer; 2023 Jul; 5(4):e220157. PubMed ID: 37477566
[TBL] [Abstract][Full Text] [Related]
23. Annotating CD38 Expression in Multiple Myeloma with [
Wei W; Zhang D; Wang C; Zhang Y; An S; Chen Y; Huang G; Liu J
Mol Pharm; 2022 Oct; 19(10):3502-3510. PubMed ID: 34846151
[TBL] [Abstract][Full Text] [Related]
24. Reassembly of
Yu B; Goel S; Ni D; Ellison PA; Siamof CM; Jiang D; Cheng L; Kang L; Yu F; Liu Z; Barnhart TE; He Q; Zhang H; Cai W
Adv Mater; 2018 Mar; 30(13):e1704934. PubMed ID: 29430735
[TBL] [Abstract][Full Text] [Related]
25. Selective ablation of TRA-1-60
White JM; Ramos N; Saliganan AD; Chung JY; Bell M; Lindquist J; Conner K; Wiesend WN; Schopperle M; Patrick SM; Kim S; Heath EI; Escorcia FE; Viola NT
Theranostics; 2023; 13(7):2057-2071. PubMed ID: 37153742
[No Abstract] [Full Text] [Related]
26. Does the Number of Bifunctional Chelators Conjugated to a mAb Affect the Biological Activity of Its Radio-Labeled Counterpart? Discussion Using the Example of mAb against CD-20 Labeled with
Karczmarczyk U; Sawicka A; Garnuszek P; Maurin M; Wojdowska W
J Med Chem; 2022 May; 65(9):6419-6430. PubMed ID: 35442675
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma.
Ryu YK; Ricker EC; Soderquist CR; Francescone MA; Lipsky AH; Amengual JE
J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013165
[TBL] [Abstract][Full Text] [Related]
28. CD38 a biomarker and therapeutic target in non-hematopoietic tumors.
Barrientos-Robledo SG; Cebada-Ruiz JA; Rodríguez-Alba JC; Baltierra-Uribe SL; Díaz Y Orea MA; Romero-Ramírez H
Biomark Med; 2022 Apr; 16(5):387-400. PubMed ID: 35195042
[TBL] [Abstract][Full Text] [Related]
29. Theranostics through Utilizing Cherenkov Radiation of Radioisotope Zr-89 with a Nanocomposite Combination of TiO
Choi PS; Lee JY; Chae JH; Wadas T; Cheng Z; Hur MG; Park JH
ACS Appl Mater Interfaces; 2023 Jan; 15(3):3689-3698. PubMed ID: 36573583
[TBL] [Abstract][Full Text] [Related]
30. ImmunoPET of CD38 with a radiolabeled nanobody: promising for clinical translation.
Shi S; Goel S; Lan X; Cai W
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2683-2686. PubMed ID: 33942140
[No Abstract] [Full Text] [Related]
31. A Versatile Platform for the Development of Radiolabeled Antibody-Recruiting Small Molecules.
Rathmann SM; Genady AR; Janzen N; Anipindi V; Czorny S; Rullo AF; Sadeghi S; Valliant JF
Mol Pharm; 2021 Jul; 18(7):2647-2656. PubMed ID: 34160225
[TBL] [Abstract][Full Text] [Related]
32. Unravelling the Potential of Lutetium-177 Labeled Pertuzumab: Targeting HER 2 Receptors for Theranostic Applications.
Sharma R; Mukherjee A; Mitra JB; Sarma HD
Int J Radiat Oncol Biol Phys; 2023 Feb; 115(2):419-425. PubMed ID: 35901977
[No Abstract] [Full Text] [Related]
33. David versus Goliath: Radiotheranostic nanomedicine as a weapon against melanoma.
Filippi L; Frantellizzi V; De Vincentis G
Cancer Treat Res Commun; 2021; 29():100478. PubMed ID: 34689017
[TBL] [Abstract][Full Text] [Related]
34.
Laffon E; Marthan R
Cancer Biother Radiopharm; 2023 Feb; 38(1):74-76. PubMed ID: 36219735
[TBL] [Abstract][Full Text] [Related]
35. Daratumumab: new indications revolving around "off-targets".
Ofran Y
Haematologica; 2021 Dec; 106(12):3032-3033. PubMed ID: 34348458
[No Abstract] [Full Text] [Related]
36. Antibody theranostics in precision medicine.
Wu Q; Yang S; Liu J; Jiang D; Wei W
Med; 2023 Feb; 4(2):69-74. PubMed ID: 36724783
[TBL] [Abstract][Full Text] [Related]
37. Correction to: Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models.
Liapis V; Tieu W; Wittwer NL; Gargett T; Evdokiou A; Takhar P; Rudd SE; Donnelly PS; Brown MP; Staudacher AH
Mol Imaging Biol; 2021 Dec; 23(6):929. PubMed ID: 34398402
[No Abstract] [Full Text] [Related]
38. LSD1-Demethylated LINC01134 Confers Oxaliplatin Resistance Through SP1-Induced p62 Transcription in HCC.
Ma L; Xu A; Kang L; Cong R; Fan Z; Zhu X; Huo N; Liu W; Xue C; Ji Q; Li W; Chu Z; Kang X; Wang Y; Sun Z; Han Y; Liu H; Gao X; Han J; You H; Zhao C; Xu X
Hepatology; 2021 Dec; 74(6):3213-3234. PubMed ID: 34322883
[TBL] [Abstract][Full Text] [Related]
39.
Kang L; Li C; Yang Q; Sutherlin L; Wang L; Chen Z; Becker KV; Huo N; Qiu Y; Engle JW; Wang R; He C; Jiang D; Xu X; Cai W
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1470-1481. PubMed ID: 34677626
[TBL] [Abstract][Full Text] [Related]
40. STAT3/LINC00671 axis regulates papillary thyroid tumor growth and metastasis via LDHA-mediated glycolysis.
Huo N; Cong R; Sun ZJ; Li WC; Zhu X; Xue CY; Chen Z; Ma LY; Chu Z; Han YC; Kang XF; Jia SH; Du N; Kang L; Xu XJ
Cell Death Dis; 2021 Aug; 12(9):799. PubMed ID: 34404767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
